Developments of russian original biological agents for the treatment of immunoinflammatory rheumatic diseases

Автор: Nasonov E.L., Mazurov V.I., Usacheva Yu.V., Chernyaeva E.V., Ustyugov Ya.yu., Ulitin A.B., Ivanov R.A.

Журнал: Научно-практическая ревматология @journal-rsp

Рубрика: Прогресс в ревматологии в XXI веке

Статья в выпуске: 2 т.55, 2017 года.

Бесплатный доступ

The paper analyzes the key biological effects of cytokines that play a central role in the pathogenesis of immunoinflammatory rheumatic diseases. Special attention is drawn to major proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-17. There are data from a preclinical study of the innovative original biological agents (BAs) designed by the JSC «BIOCAD»: BCD-085, a humanized anti-IL-17 monoclonal antibody, BCD-089, a humanized anti-IL-6 receptor monoclonal antibody, and BCD-121, a humanized bispecific anti-TNF-α and anti-IL-17 monoclonal antibody. The preclinical findings prove the specific activity of the drugs in suppressing the inflammatory process, as well as the low toxicity and good tolerance in animals, which could justify investigation of the the drugs during human clinical trials and open up prospects for effective and affordable treatment in Russian patients.

Еще

Anti-il-17 monoclonal antibodies, anti-il-6 receptor monoclonal antibodies, bispecific anti-tnf-α and anti-il-17 monoclonal antibodies

Короткий адрес: https://sciup.org/14945810

IDR: 14945810   |   DOI: 10.14412/1995-4484-2017-201-210

Статья научная